Foundry CBOperProf Industry-Neutral Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1NVDA | NVIDIA CORP | Technology | $4.91T | 25.08% |
2AAPL | APPLE INC | Technology | $4.90T | 25.05% |
3AMZN | AMAZON COM INC | Consumer Cyclical | $2.66T | 13.59% |
4META | META PLATFORMS INC | Communication Services | $1.64T | 8.38% |
5MA | MASTERCARD INC | Financial Services | $480.32B | 2.45% |
6LRCX | LAM RESEARCH CORP | Technology | $391.80B | 2.00% |
7KO | COCA COLA CO | Consumer Defensive | $350.91B | 1.79% |
8NFLX | NETFLIX INC | Communication Services | $290.47B | 1.48% |
9KLAC | KLA CORP | Technology | $277.91B | 1.42% |
10PEP | PEPSICO INC | Consumer Defensive | $187.15B | 0.96% |
11QCOM | QUALCOMM INC | Technology | $181.06B | 0.93% |
12STX | SEAGATE TECHNOLOGY HOLDINGS PLC | Technology | $176.62B | 0.90% |
13WDC | WESTERN DIGITAL CORP | Technology | $164.49B | 0.84% |
14APP | APPLOVIN CORP | Technology | $142.62B | 0.73% |
15SCCO | SOUTHERN COPPER CORP | Basic Materials | $142.48B | 0.73% |
16BKNG | BOOKING HOLDINGS INC | Industrials | $140.78B | 0.72% |
17SYK | STRYKER CORP | Healthcare | $122.63B | 0.63% |
18ISRG | INTUITIVE SURGICAL INC | Healthcare | $122.33B | 0.63% |
19SBUX | STARBUCKS CORP | Consumer Cyclical | $120.23B | 0.61% |
20MDT | MEDTRONIC PLC | Healthcare | $106.50B | 0.54% |
21ADBE | ADOBE INC | Technology | $94.31B | 0.48% |
22DDOG | DATADOG INC | Technology | $92.08B | 0.47% |
23CDNS | CADENCE DESIGN SYSTEMS INC | Technology | $91.05B | 0.47% |
24MMM | 3M CO | Industrials | $83.37B | 0.43% |
25HCA | HCA HEALTHCARE INC | Healthcare | $82.34B | 0.42% |
26BSX | BOSTON SCIENTIFIC CORP | Healthcare | $65.44B | 0.33% |
27EA | ELECTRONIC ARTS INC | Communication Services | $52.38B | 0.27% |
28ALAB | ASTERA LABS INC | Technology | $52.04B | 0.27% |
29EW | EDWARDS LIFESCIENCES CORP | Healthcare | $49.36B | 0.25% |
30ADSK | AUTODESK INC | Technology | $46.07B | 0.24% |
31MSCI | MSCI INC | Financial Services | $45.77B | 0.23% |
32IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 0.23% |
33KDP | KEURIG DR PEPPER INC | Consumer Defensive | $42.05B | 0.21% |
34NTRA | NATERA INC | Healthcare | $38.87B | 0.20% |
35RBLX | ROBLOX CORP | Communication Services | $37.02B | 0.19% |
36WDAY | WORKDAY INC | Technology | $35.76B | 0.18% |
37ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 0.18% |
38RDDT | REDDIT INC | Communication Services | $34.88B | 0.18% |
39ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 0.18% |
40UI | UBIQUITI INC | Technology | $33.04B | 0.17% |
41DXCM | DEXCOM INC | Healthcare | $29.58B | 0.15% |
42FICO | FAIR ISAAC CORP | Technology | $29.15B | 0.15% |
43RMD | RESMED INC | Healthcare | $28.86B | 0.15% |
44FTI | TECHNIPFMC PLC | Energy | $28.73B | 0.15% |
45GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $28.69B | 0.15% |
46ILMN | ILLUMINA INC | Healthcare | $28.24B | 0.14% |
47OTIS | OTIS WORLDWIDE CORP | Industrials | $28.18B | 0.14% |
48MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $26.47B | 0.14% |
49VRSK | VERISK ANALYTICS INC | Industrials | $26.29B | 0.13% |
50VRSN | VERISIGN INC | Technology | $25.27B | 0.13% |
51EXPD | EXPEDITORS INTERNATIONAL OF WASHINGTON INC | Industrials | $23.91B | 0.12% |
52TEAM | ATLASSIAN CORP | Technology | $23.67B | 0.12% |
53INCY | INCYTE CORP | Healthcare | $23.42B | 0.12% |
54STZ | CONSTELLATION BRANDS INC | Consumer Defensive | $22.69B | 0.12% |
55NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.09% |
56LSCC | LATTICE SEMICONDUCTOR CORP | Technology | $17.16B | 0.09% |
57THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 0.09% |
58NTNX | NUTANIX INC | Technology | $14.89B | 0.08% |
59DECK | DECKERS OUTDOOR CORP | Consumer Cyclical | $14.79B | 0.08% |
60LOGI | LOGITECH INTERNATIONAL SA | Technology | $14.76B | 0.08% |
61EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.07% |
62MLI | MUELLER INDUSTRIES INC | Industrials | $13.08B | 0.07% |
63PINS | PINTEREST INC | Communication Services | $13.00B | 0.07% |
64ALGN | ALIGN TECHNOLOGY INC | Healthcare | $12.66B | 0.06% |
65PEN | PENUMBRA INC | Healthcare | $12.52B | 0.06% |
66GDDY | GODADDY INC | Technology | $12.49B | 0.06% |
67NYT | NEW YORK TIMES CO | Consumer Cyclical | $12.29B | 0.06% |
68BF.B | BROWN FORMAN CORP | Consumer Defensive | $11.74B | 0.06% |
69HAS | HASBRO INC | Consumer Cyclical | $11.54B | 0.06% |
70HUBS | HUBSPOT INC | Technology | $11.49B | 0.06% |
71PODD | INSULET CORP | Healthcare | $11.36B | 0.06% |
72CART | INSTACART (MAPLEBEAR INC) | Consumer Cyclical | $10.77B | 0.06% |
73DPZ | DOMINOS PIZZA INC | Consumer Cyclical | $10.72B | 0.05% |
74ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 0.05% |
75GMED | GLOBUS MEDICAL INC | Healthcare | $10.45B | 0.05% |
76DOCU | DOCUSIGN INC | Technology | $10.07B | 0.05% |
77CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.05% |
78MANH | MANHATTAN ASSOCIATES INC | Technology | $9.66B | 0.05% |
79MTCH | MATCH GROUP INC | Communication Services | $9.13B | 0.05% |
80ETSY | ETSY INC | Consumer Cyclical | $7.98B | 0.04% |
81TAP | MOLSON COORS BEVERAGE CO | Consumer Defensive | $7.28B | 0.04% |
82SLAB | SILICON LABORATORIES INC | Technology | $7.17B | 0.04% |
83DBX | DROPBOX INC | Technology | $7.14B | 0.04% |
84CRUS | CIRRUS LOGIC INC | Technology | $6.98B | 0.04% |
85SNDR | SCHNEIDER NATIONAL INC | Industrials | $6.69B | 0.03% |
86MSA | MSA SAFETY INC | Industrials | $6.60B | 0.03% |
87MXL | MAXLINEAR INC | Technology | $6.43B | 0.03% |
88APPF | APPFOLIO INC | Technology | $6.36B | 0.03% |
89DUOL | DUOLINGO INC | Technology | $6.24B | 0.03% |
90TFX | TELEFLEX INC | Healthcare | $5.96B | 0.03% |
91SEZL | SEZZLE INC | Financial Services | $5.87B | 0.03% |
92QLYS | QUALYS INC | Technology | $5.61B | 0.03% |
93TXG | 10X GENOMICS INC | Healthcare | $5.55B | 0.03% |
94PEGA | PEGASYSTEMS INC | Technology | $5.39B | 0.03% |
95TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.03% |
96RELY | REMITLY GLOBAL INC | Technology | $5.08B | 0.03% |
97KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.03% |
98MMED | MINIMED GROUP INC | Healthcare | $4.75B | 0.02% |
99LIVN | LIVANOVA PLC | Healthcare | $4.43B | 0.02% |
100VKTX | VIKING THERAPEUTICS INC | Healthcare | $4.31B | 0.02% |
101BOX | BOX INC | Technology | $4.22B | 0.02% |
102CALM | CAL-MAINE FOODS INC | Consumer Defensive | $4.20B | 0.02% |
103COCO | VITA COCO COMPANY INC | Consumer Defensive | $4.18B | 0.02% |
104EXTR | EXTREME NETWORKS INC | Technology | $3.97B | 0.02% |
105DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.02% |
106QS | QUANTUMSCAPE CORP | Consumer Cyclical | $3.60B | 0.02% |
107NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 0.02% |
108HAE | HAEMONETICS CORP | Healthcare | $3.54B | 0.02% |
109RNG | RINGCENTRAL INC | Technology | $3.46B | 0.02% |
110RCUS | ARCUS BIOSCIENCES INC | Healthcare | $3.44B | 0.02% |
111IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 0.02% |
112CARG | CARGURUS INC | Consumer Cyclical | $3.16B | 0.02% |
113XNDU | XANADU QUANTUM TECHNOLOGIES LTD | Technology | $2.98B | 0.02% |
114RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 0.01% |
115ADEA | ADEIA INC | Technology | $2.80B | 0.01% |
116AMBA | AMBARELLA INC | Technology | $2.71B | 0.01% |
117GRND | GRINDR INC | Technology | $2.71B | 0.01% |
118ALRM | ALARMCOM HOLDINGS INC | Technology | $2.63B | 0.01% |
119TMDX | TRANSMEDICS GROUP INC | Healthcare | $2.56B | 0.01% |
120PTON | PELOTON INTERACTIVE INC | Consumer Cyclical | $2.55B | 0.01% |
121CALX | CALIX INC | Technology | $2.50B | 0.01% |
122CMPR | CIMPRESS PLC | Communication Services | $2.49B | 0.01% |
123NRIX | NURIX THERAPEUTICS INC | Healthcare | $2.40B | 0.01% |
124BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.01% |
125BHVN | BIOHAVEN LTD | Healthcare | $2.32B | 0.01% |
126LMAT | LEMAITRE VASCULAR INC | Healthcare | $2.32B | 0.01% |
127INTA | INTAPP INC | Technology | $2.24B | 0.01% |
128HTFL | HEARTFLOW INC | Healthcare | $2.15B | 0.01% |
129AXGN | AXOGEN INC | Healthcare | $2.12B | 0.01% |
130CDNA | CAREDX INC | Healthcare | $2.05B | 0.01% |
131PLSE | PULSE BIOSCIENCES INC | Healthcare | $1.98B | 0.01% |
132HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.01% |
133APPN | APPIAN CORP | Technology | $1.92B | 0.01% |
134SAM | BOSTON BEER CO INC | Consumer Defensive | $1.86B | 0.01% |
135VRDN | VIRIDIAN THERAPEUTICS INC | Healthcare | $1.86B | 0.01% |
136NVCR | NOVOCURE LTD | Healthcare | $1.84B | 0.01% |
137SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.01% |
138SONO | SONOS INC | Technology | $1.80B | 0.01% |
139ASAN | ASANA INC | Technology | $1.77B | 0.01% |
140ATRC | ATRICURE INC | Healthcare | $1.77B | 0.01% |
141DV | DOUBLEVERIFY HOLDINGS INC | Technology | $1.75B | 0.01% |
142ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.01% |
143INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.01% |
144ARLO | ARLO TECHNOLOGIES INC | Basic Materials | $1.45B | 0.01% |
145YELP | YELP INC | Communication Services | $1.44B | 0.01% |
146AIP | ARTERIS INC | Technology | $1.43B | 0.01% |
147RMIX | SUNCRETE INC | Basic Materials | $1.40B | 0.01% |
148WINA | WINMARK CORP | Consumer Cyclical | $1.39B | 0.01% |
149REAL | THEREALREAL INC | Consumer Cyclical | $1.35B | 0.01% |
150NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.01% |
151IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.01% |
152LQDT | LIQUIDITY SERVICES INC | Consumer Cyclical | $1.23B | 0.01% |
153CBRL | CRACKER BARREL OLD COUNTRY STORE INC | Consumer Cyclical | $1.20B | 0.01% |
154HTLD | HEARTLAND EXPRESS INC | Industrials | $1.19B | 0.01% |
155DRTS | ALPHA TAU MEDICAL LTD | Healthcare | $1.19B | 0.01% |
156TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 0.01% |
157MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.01% |
158CRTO | CRITEO SA | Communication Services | $1.13B | 0.01% |
159UPWK | UPWORK INC | Industrials | $1.12B | 0.01% |
160EYPT | EYEPOINT INC | Healthcare | $1.12B | 0.01% |
161BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.01% |
162FBRX | FORTE BIOSCIENCES INC | Healthcare | $1.00B | 0.01% |
163VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.01% |
164ANNX | ANNEXON INC | Healthcare | $950M | 0.00% |
165EVER | EVERQUOTE INC | Communication Services | $925M | 0.00% |
166TDUP | THREDUP INC | Consumer Cyclical | $852M | 0.00% |
167AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $823M | 0.00% |
168DSP | VIANT TECHNOLOGY INC | Technology | $754M | 0.00% |
169WEST | WESTROCK COFFEE CO | Consumer Defensive | $749M | 0.00% |
170AURA | AURA BIOSCIENCES INC | Healthcare | $723M | 0.00% |
171PHR | PHREESIA INC | Healthcare | $662M | 0.00% |
172TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.00% |
173FAC | FACTORIAL ENERGY INC | Industrials | $610M | 0.00% |
174NRDS | NERDWALLET INC | Communication Services | $609M | 0.00% |
175FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.00% |
176OOMA | OOMA INC | Communication Services | $568M | 0.00% |
177ANGO | ANGIODYNAMICS INC | Healthcare | $558M | 0.00% |
178NPCE | NEUROPACE INC | Healthcare | $548M | 0.00% |
179YEXT | YEXT INC | Technology | $535M | 0.00% |
180RGNX | REGENXBIO INC | Healthcare | $511M | 0.00% |
181DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.00% |
182PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.00% |
183RLGT | RADIANT LOGISTICS INC | Industrials | $431M | 0.00% |
184SGU | STAR GROUP LP | Energy | $430M | 0.00% |
185CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.00% |
186STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.00% |
187CRNC | CERENCE INC | Technology | $390M | 0.00% |
188NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $359M | 0.00% |
189XPER | XPERI INC | Technology | $352M | 0.00% |
190ELMD | ELECTROMED INC | Healthcare | $349M | 0.00% |
191CV | CAPSOVISION INC | Healthcare | $335M | 0.00% |
192BKKT | BAKKT INC | Technology | $323M | 0.00% |
193QTTB | Q32 BIO INC | Healthcare | $255M | 0.00% |
194ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.00% |
195GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $240M | 0.00% |
196SMTI | SANARA MEDTECH INC | Healthcare | $229M | 0.00% |
197SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.00% |
198KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.00% |
199AGEN | AGENUS INC | Healthcare | $209M | 0.00% |
200ANIK | ANIKA THERAPEUTICS INC | Healthcare | $203M | 0.00% |
201PDEX | PRO DEX INC | Healthcare | $183M | 0.00% |
202EGAN | EGAIN CORP | Technology | $180M | 0.00% |
203INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.00% |
204ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.00% |
205VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.00% |
206CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.00% |
207INSG | INSEEGO CORP | Technology | $122M | 0.00% |
208SOTK | SONO TEK CORP | Technology | $86M | 0.00% |
209CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.00% |
210ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.00% |
211BODI | BEACHBODY COMPANY INC | Communication Services | $75M | 0.00% |
212BGSF | BGSF INC | Industrials | $65M | 0.00% |
213XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $19.57T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 100% toward Large, 83% toward Growth. Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 213 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual47.9%Margin-27.1%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual25.1%Margin-0.1%Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Required<= 25.0%Actual27.0%Margin-2.0%
At least 50% of total assets must sit in cash, government securities, other RICs, and other securities limited to 5% of assets and 10% of the issuer's voting securities per issuer.
Required>= 50.0%Actual47.9%Margin-2.1%Arithmetically entailed by '40 Act 5(b)(1) diversification (75%/5% asset leg) — it cannot fail independently, so it is reported outside the tally rather than counted as a separate check.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 213 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Annual return moved the other way (+1.5pp), so Sharpe and return disagree here — the change is partly a shift in volatility rather than in return.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 28.6% | 8.4% |
| 3 yearsp.a. | 25.9% | 12.2% |
| 5 yearsp.a. | 14.6% | 13.7% |
| 10 yearsp.a. | 17.1% | 6.2% |
| Since inceptionp.a. | 12.1% | 5.6% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 11.9% | 5.3% |
| 2025 | 22.1% | 0.4% |
| 2024 | 43.4% | 36.3% |
| 2023 | 50.1% | 12.5% |
| 2022 | -36.2% | -5.4% |
| 2021 | 23.3% | 21.7% |
| 2020 | 35.5% | 2.0% |
| 2019 | 22.7% | -10.0% |
| 2018 | 4.3% | 10.5% |
| 2017 | 12.7% | -9.0% |
| 2016 | 9.9% | -6.5% |
| 2015 | 15.9% | 38.6% |
| 2014 | 16.9% | 27.5% |
| 2013 | 35.9% | 6.1% |
| 2012 | 12.3% | 6.7% |
| 2011 | 6.4% | 0.1% |
| 2010 | 10.7% | -9.8% |
| 2009 | 57.3% | 4.4% |
| 2008 | -38.7% | 14.3% |
| 2007 | 11.4% | 0.3% |
| 2006 | 9.1% | -6.5% |
| 2005 | 6.1% | 5.3% |
| 2004 | 18.2% | -8.8% |
| 2003 | 39.0% | -15.2% |
| 2002 | -14.3% | 14.4% |
| 2001 | -17.5% | 7.5% |
| 2000 | -16.1% | 36.0% |
| 1999 | 58.2% | 2.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry CBOperProf Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a CBOperProf signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.